Neuroblastoma (Pediatric)

Neuroblastoma is a cancer of the sympathetic nervous system that arises from primitive neural crest cells — the embryonic precursors of the adrenal glands, the paraspinal sympathetic ganglia, and related structures. It is the most common extracranial solid tumor in children and the most common cancer in infants under one year of age. Most neuroblastoma is diagnosed before the age of 5, with a median age at diagnosis of approximately 17–18 months. It is extremely rare in adults.

The tumor can arise anywhere along the sympathetic nervous system — most commonly in the adrenal glands (approximately 40% of cases), but also in the paraspinal ganglia of the chest, abdomen, and pelvis, and occasionally in the neck. Neuroblastoma is biologically extraordinary in its range — from tumors that spontaneously disappear without treatment in young infants, to one of the most aggressive childhood cancers when it presents as advanced-stage disease in older children with MYCN amplification.

Risk classification in neuroblastoma integrates multiple variables to predict how the disease will behave and how intensively it must be treated. The most important factor is MYCN amplification — if the tumor carries more than 10 copies of the MYCN gene, it is classified as high-risk regardless of all other features. Other high-risk designators include: metastatic disease (Stage M) in children over 18 months of age; and in some systems, 11q deletion or other adverse chromosomal features in otherwise intermediate-risk tumors.

High-risk neuroblastoma requires approximately 12–18 months of intensive treatment — induction chemotherapy, surgery, high-dose chemotherapy with autologous stem cell transplant (or tandem transplants), consolidation radiation, isotretinoin maintenance, and anti-GD2 immunotherapy (dinutuximab). Despite this intensity, approximately 40–50% of high-risk patients relapse. Risk group assignment must be based on complete molecular testing — incomplete testing at diagnosis can misclassify patients. If the molecular workup was incomplete at your child's diagnosis, this should be addressed urgently.

MYCN is a proto-oncogene that encodes a transcription factor driving cell proliferation. Normally, the MYCN gene exists in two copies in each cell (one on each chromosome 2). MYCN amplification means the tumor cells have accumulated many additional copies — by definition, more than 10 — causing massively increased MYCN protein production. This drives rapid, uncontrolled proliferation of neuroblastoma cells and resistance to differentiation.

MYCN amplification is present in approximately 20–25% of neuroblastomas and is the single most powerful adverse prognostic marker in the disease. A neuroblastoma with MYCN amplification is classified as high-risk regardless of stage, age, or histology — even if it appears localized on imaging. MYCN testing by FISH (fluorescence in situ hybridization) on tumor tissue is mandatory for every neuroblastoma diagnosis. Without this result, risk classification is incomplete and treatment planning may be inappropriate.

MIBG (meta-iodobenzylguanidine) is a chemical analogue of norepinephrine that is actively taken up by the sympathoadrenal cells that give rise to neuroblastoma. Because most neuroblastoma cells express the norepinephrine transporter, they selectively concentrate MIBG — making it both a highly specific imaging agent and a potential vehicle for targeted radiotherapy.

For imaging (staging and response assessment), iodine-123 (¹²³I)-labeled MIBG is used for whole-body scintigraphy to identify all sites of neuroblastoma disease with high sensitivity — including bone metastases, bone marrow involvement, and soft tissue deposits not visible on CT or MRI. For treatment, iodine-131 (¹³¹I)-labeled MIBG delivers targeted radiation directly to MIBG-avid neuroblastoma cells throughout the body and is approved for relapsed MIBG-avid neuroblastoma. It is also being studied as an additional consolidation component in upfront high-risk treatment. Confirming MIBG avidity of the tumor at diagnosis is essential — it determines both the monitoring approach and eligibility for therapeutic MIBG.

GD2 (disialoganglioside) is a glycolipid found on the surface of virtually all neuroblastoma cells, as well as on certain normal tissues including peripheral pain fibers and the central nervous system. Anti-GD2 antibodies — including dinutuximab (the US standard) and dinutuximab beta (the European standard) — bind to GD2 on neuroblastoma cells and flag them for destruction by the immune system, primarily through antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells.

Anti-GD2 immunotherapy combined with GM-CSF, IL-2, and isotretinoin is now standard maintenance therapy for high-risk neuroblastoma after completing high-dose chemotherapy consolidation. The ANBL0032 trial (COG) demonstrated significantly improved event-free and overall survival compared to isotretinoin alone. The main side effect is intense neuropathic pain during infusion — from GD2 expression on peripheral pain fibers — which is expected and managed with opioid analgesia. For relapsed disease, naxitamab is an approved humanized anti-GD2 antibody with activity in bone and bone marrow relapse.

Yes — ALK mutation is the most important actionable molecular alteration in neuroblastoma currently. Activating ALK mutations (most commonly at amino acid positions 1174, 1275, and 1245) occur in approximately 8–10% of neuroblastomas somatically and are the most common cause of familial neuroblastoma when inherited in the germline. ALK mutations co-occur with MYCN amplification in many cases and confer additional adverse prognosis.

The most important development for ALK-mutant neuroblastoma is the ongoing evaluation of lorlatinib — a third-generation ALK inhibitor with excellent CNS penetration — in pivotal clinical trials for ALK-mutant high-risk neuroblastoma. Lorlatinib added to standard induction chemotherapy has shown very high complete response rates in early-phase evaluations. These trials are actively enrolling, and identification of ALK mutation at diagnosis is therefore critically important for trial eligibility. Crizotinib (an earlier ALK inhibitor) has also shown activity in ALK-mutant neuroblastoma and may be available in some centers outside of formal trials. If ALK mutation was found in your child's tumor, specialist neuroblastoma second opinion to assess trial eligibility for lorlatinib-based regimens is strongly recommended.

Relapsed high-risk neuroblastoma represents one of the most difficult situations in pediatric oncology, with limited established curative options. The approach depends on the disease's characteristics at relapse: MIBG-avid relapsed neuroblastoma can be treated with therapeutic ¹³¹I-MIBG (approved and active), often combined with additional chemotherapy. ALK mutation testing at relapse biopsy is essential — if ALK mutation is present (including as a newly acquired mutation), lorlatinib or crizotinib trials are a priority. Anti-GD2 antibody retreatment with naxitamab (approved for bone and bone marrow relapse) provides disease control in some patients.

For children who achieve a second remission with salvage therapy, second autologous transplant or allogeneic stem cell transplantation may be considered. GD2-directed CAR-T cell therapy — available in clinical trials, with active programs in China, the US, and Europe — has shown meaningful responses in heavily pretreated relapsed neuroblastoma and represents the most promising emerging option for multiply relapsed disease. Clinical trial enrollment is strongly recommended for all relapsed neuroblastoma patients, and specialist center review is essential to identify the most appropriate current trial option.

Yes — neuroblastoma is one of the most active areas of pediatric oncology research globally, and China has significant and growing activity particularly in cellular therapy. In China, GD2-directed CAR-T cell programs for relapsed/refractory neuroblastoma are in early-phase clinical evaluation at specialist pediatric oncology centers, with responses including complete responses reported in children who had no remaining standard treatment options. These programs are accessible through specialist centers and represent an important option for families who have exhausted available Western treatments.

In North America, the Children's Oncology Group (COG) runs active trials including the ANBL1521 study evaluating lorlatinib in ALK-mutant high-risk neuroblastoma, tandem transplant protocols, and MIBG combination studies. European SIOPEN trials evaluate similar questions in a different protocol framework. In India, trial availability is more limited, but neuroblastoma cases at major centers including Tata Memorial Hospital and AIIMS are managed according to COG or SIOPEN protocols. CancerFax can assist in reviewing the child's molecular profile and treatment history against currently open trials globally and can facilitate coordination with enrolling centers, including in China.

Yes. CancerFax supports families of children with neuroblastoma through the full treatment navigation process. We begin with a detailed review of the biopsy report, MYCN FISH result, ALK mutation testing, chromosomal copy number profile, DNA ploidy, MIBG scan findings, and treatment history to confirm the risk classification and identify which treatment options are most relevant — because in neuroblastoma, these molecular details determine everything.

Based on this review, we identify which treatment approaches apply — from the appropriate cooperative group protocol for newly diagnosed disease, to anti-GD2 immunotherapy access, ¹³¹I-MIBG therapy eligibility, lorlatinib trial enrollment for ALK-mutant disease, DFMO extended maintenance, and GD2-CAR-T programs at specialist centers in China and globally for relapsed disease. We coordinate specialist second opinion consultations with dedicated neuroblastoma pediatric oncologists at high-volume centers, and facilitate international treatment navigation for families seeking access to clinical trials or advanced therapies not yet available in their home country. Send your child's medical reports to get started.